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OBJECTIVE—Clinical reports link use of the glucagon-like
peptide-1 receptor (GLP-1R) agonists exenatide and liraglutide to
pancreatitis. However, whether these agents act on the exocrine
pancreas is poorly understood.
RESEARCH DESIGN AND METHODS—We assessed whether
the antidiabetic agents exendin (Ex)-4, liraglutide, the dipeptidyl
peptidase-4 inhibitor sitagliptin, or the biguanide metformin were
associated with changes in expression of genes associated with
the development of experimental pancreatitis. The effects of Ex-4
when administered before or after the initiation of caerulein-
induced experimental pancreatitis were determined. The impor-
tance of endogenous GLP-1R signaling for gene expression in the
exocrine pancreas and the severity of pancreatitis was assessed
in Glp1r
/ mice.
RESULTS—Acute administration of Ex-4 increased expres-
sion of egr-1 and c-fos in the exocrine pancreas. Administra-
tion of Ex-4 or liraglutide for 1 week increased pancreas
weight and induced expression of mRNA transcripts encoding
the anti-inﬂammatory proteins pancreatitis-associated protein
(PAP) (RegIII) and RegIII. Chronic Ex-4 treatment of high-
fat–fed mice increased expression of PAP and reduced pan-
creatic expression of mRNA transcripts encoding for the
proinﬂammatory monocyte chemotactic protein-1, tumor ne-
crosis factor-, and signal transducer and activator of tran-
scription-3. Sitagliptin and metformin did not signiﬁcantly
change pancreatic gene expression proﬁles. Ex-4 administered
before or after caerulein did not modify the severity of
experimental pancreatitis, and levels of pancreatic edema and
serum amylase were comparable in caerulein-treated
Glp1r
/ versus Glp1r
/ mice.
CONCLUSIONS—These ﬁndings demonstrate that GLP-1 re-
ceptor activation increases pancreatic mass and selectively mod-
ulates the expression of genes associated with pancreatitis.
However, activation or genetic elimination of GLP-1R signaling
does not modify the severity of experimental pancreatitis in
mice. Diabetes 58:2148–2161, 2009
G
lucagon-like peptide (GLP)-1, a peptide hor-
mone secreted by enteroendocrine cells in the
distal small bowel and colon, exerts a diverse
set of complementary actions on islet -cells,
resulting in glucose-dependent augmentation of insulin
biosynthesis and secretion (1). GLP-1 also restores glu-
cose sensitivity to diabetic -cells and promotes expan-
sion of -cell mass via stimulation of -cell proliferation
and enhancement of -cell survival (2). Moreover, exoge-
nous GLP-1 administration inhibits glucagon secretion and
gastric emptying and induces satiety, leading to weight
loss after prolonged GLP-1 receptor (GLP-1R) activation
(3). Taken together, these actions of GLP-1 lead to signif-
icant improvement in glucose homeostasis and have fos-
tered the development of GLP-1R agonists, exempliﬁed by
synthetic exendin (Ex)-4, for the treatment of type 2
diabetes (3,4).
The majority of studies examining GLP-1 biology in the
pancreas has focused on - and -cells within the endo-
crine pancreas; however, GLP-1 exerts a number of ac-
tions in the exocrine pancreas. GLP-1R agonists induce
transdifferentiation of pancreatic exocrine cells to an
endocrine cell phenotype in vitro (5), and GLP-1 inhibits
hypoglycemia-induced pancreatic bicarbonate and protein
secretion in the isolated perfused pig pancreas (6). More-
over, exogenous GLP-1 induces neural transmission con-
verging on the pancreas via depolarization of neurons
within the dorsal motor nucleus of the vagus that project
to the exocrine pancreas (7).
Although the biology of GLP-1 action in the exocrine
pancreas remains poorly understood, the clinical use of
the ﬁrst approved GLP-1R agonist, exenatide, has been
associated with case reports of pancreatitis, and some
have speculated this may be related to the venomous
origin of the Ex-4 peptide from the lizard (8). Although
there is limited scientiﬁc information linking GLP-1 recep-
tor activation to the pathogenesis of pancreatic inﬂamma-
tion, pancreatitis has also been reported in clinical trials of
the human GLP-1R agonist liraglutide (9). In contrast,
analysis of a health care claims database did not reveal an
increased incidence of pancreatitis in hospitalized patients
previously treated with exenatide versus other antidia-
betic agents (10).
As GLP-1 inhibits pancreatic exocrine secretion (6), a
putative mechanism associated with the development of
pancreatitis (11), it seems possible that sustained GLP-1
receptor activation will increase the susceptibility for
development of pancreatic inﬂammation. Ex-4 regulates
the pancreatic expression of the Reg gene family (12), and
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2148 DIABETES, VOL. 58, SEPTEMBER 2009changes in expression of RegIII (also known as pancre-
atitis-associated protein [PAP]) have been associated with
divergent effects on pancreatitis susceptibility and pancre-
atic necrosis in vivo (13,14).
Accordingly, we examined whether GLP-1 receptor ac-
tivation modulates expression of genes known to be
associated with the development of inﬂammation or acute
pancreatitis in mice. We employed two structurally dis-
tinct GLP-1R agonists, Ex-4 and liraglutide, as well as a
dipeptidyl peptidase (DPP)-4 inhibitor, sitagliptin, and the
biguanide metformin to assess pancreatitis-associated
gene expression in mice. The effect of Ex-4 administra-
tion before or after the administration of low-dose
caerulein, a chemical cholecystokinin (CCK) mimic that
produces secreatogue-induced pancreatitis (15), was
assessed in wild-type mice, and changes in pancreatic
gene expression and the susceptibility to pancreatitis
were analyzed in Glp1r
/ mice.
Experimental procedures. Experiments were carried
out according to protocols approved by the animal care
committees of the University Health Network and Mount
Sinai Hospital. Mice were housed under a 12-h light/dark
cycle with access to standard or high-fat rodent diet (45%
kcal from fat; Research Diets, New Brunswick, NJ). Male
C57Bl/6J mice (8–10 weeks old) were obtained from
Taconic Laboratories (Hudson, NY) and were allowed to
acclimatize to the animal facility for 7 days before each
experiment. Glp1r
/ mice in the C57Bl/6J background
were generated as described (16).
Reagents. Ex-4 was from Chi Scientiﬁc (Maynard, MA)
and dissolved in PBS. Forskolin and caerulein were from
Sigma Chemical (St. Louis, MO). Caerulein was dissolved
in saline (0.9% NaCl) and forskolin in DMSO. Liraglutide
was from Novo Nordisk (Bagsværd, Denmark). Sitagliptin
was from Merck (Rahway, NJ).
Induction of experimental pancreatitis. Pancreatitis
was induced in 9- to 11-week-old male C57Bl/6J mice or
3-month-old male Glp1r
/ and littermate control
Glp1r
/ mice using the CCK receptor agonist caerulein
(17). Caerulein dose-response experiments were per-
formed in male 9- to 11-week-old C57Bl/6J mice to identify
a submaximal dose of caerulein that would produce a low
level of pancreatic inﬂammation. Secretagogue-induced
pancreatitis was elicited by administration of ﬁve sequen-
tial hourly intraperitoneal injections of caerulein, at doses
of 6, 12, 24, or 50 g/kg body wt as described (11,17,18);
control animals received an equal volume of saline. Mice
were killed by CO2 inhalation 1 h after the ﬁnal caerulein
injection.
Pretreatment with Ex-4. To assess whether prior
GLP-1R activation exacerbates the subsequent develop-
ment of pancreatitis, male C57Bl/6J mice were injected
(intraperitoneally) twice daily with either 10 nmol/kg Ex-4
or PBS for 7 days. Sixteen hours after the last Ex-4
injection, mice were administered 5 hourly intraperitoneal
injections of caerulein at 3 or 6 g/kg body wt, as
indicated, and killed by CO2 inhalation 1 h after the ﬁnal
caerulein injection.
Posttreatment with Ex-4. To assess whether a low level
of pancreatitis was worsened by subsequent GLP-1R acti-
vation, male C57Bl/6J mice were administered 5 hourly
intraperitoneal injections of caerulein (6 g/kg) followed
by twice daily intraperitoneal injections with either 10
nmol/kg Ex-4 or PBS for up to 6 days. Mice were killed 1,
24, 72, or 144 h (day 0, 1, 3, and 6, respectively) after the
ﬁnal caerulein injection such that mice killed on day 1
received two injections of PBS or Ex-4, one in the evening
(3 h after the last caerulein injection) and one in the
morning (6 h before being killed). Similarly, the ﬁnal
injection with Ex-4 or PBS was 6 h before being killed for
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FIG. 1. Acute induction of egr-1 and c-fos transcripts by Ex-4. Male
C57Bl/6J mice were subcutaneously injected with a single dose of Ex-4
(1 g) or vehicle alone (PBS). A: Total RNA was isolated from pancreas
45 min after injections and reverse transcribed, and the levels of the
indicated transcripts were determined by real-time PCR, normalized to
18S rRNA content, and shown relative to the control (PBS)-treated
group. Results are expressed as means  SE. ***P < 0.001 PBS- versus
Ex-4–treated mice, n  4 in each group. Immunohistochemical local-
ization of egr-1 (B) and c-fos (C) in the pancreas of mice treated for 45
min with vehicle (PBS) or Ex-4. Photomicrographs are representative
of four mice per group. Islets are represented with an i. Magniﬁcation
200 or 400. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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2150 DIABETES, VOL. 58, SEPTEMBER 2009all remaining mice (day 3 and 6). To determine whether
loss of GLP-1R signaling protected mice from development
of experimental pancreatic inﬂammation, pancreatitis was
induced in 3-month-old male Glp1r
/ and Glp1r
/ mice
by administration of 5 hourly intraperitoneal injections of
caerulein (6 g/kg). Mice were killed by CO2 inhalation 1 h
after the ﬁnal caerulein injection.
Acute peptide administration and high-fat feeding
studies. To assess whether GLP-1 receptor activation
regulates gene expression in the exocrine pancreas of
C
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FIG. 2. GLP-1R agonists increase pancreatic weight and regulate gene expression in a GLP-1R–dependent manner. A: Pancreas weight of mice
treated twice daily with the indicated doses of Ex-4 for 1 week is shown as a percentage of the ﬁnal body weight (left panel) or absolute pancreas
weight (right panel). Results are expressed as means  SE. *P < 0.05 PBS- versus Ex-4–treated mice, n  5 in each group. B: Expression proﬁles
of genes associated with pancreatitis in the pancreas of mice treated twice daily for 1 week with the indicated doses of Ex-4 (0.1–10 nmol/kg).
Total RNA was isolated from pancreas samples and reverse transcribed, and the levels of the indicated transcripts were determined by real-time
quantitative PCR, normalized to levels of 18S or cyclophillin mRNA transcripts (for SOCS3, STAT3, junB, ndrg1, and iﬁtm3), and shown relative
to the control (PBS)-treated group. Results are expressed as means  SE. **P < 0.01, ***P < 0.001 PBS- versus Ex-4–treated mice, n  5 in each
group. Pancreas weight shown as a percentage of the ﬁnal body weight (left panel) or absolute pancreas weight (right panel)( C), and expression
proﬁles of genes associated with pancreatitis (D) in the pancreas of wild-type Glp1r
/ and Glp1r
/ mice treated twice daily for 1 week with 75
g/kg liraglutide. Levels of mRNA transcripts were determined by real-time quantitative PCR, normalized to the 18S rRNA content, and shown
relative to control (PBS)-treated wild-type mice. Results are expressed as means  SE. *P < 0.05, **P < 0.01 PBS- versus liraglutide-treated mice,
#P < 0.05, ##P < 0.01 wild-type versus Glp1r
/ mice, n  3 in each group.
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neously with a single dose of Ex-4 (1 g), Ex-4  15%
glucose (G  X), or PBS, and mice were killed 30, 45, 60,
or 90 min later by CO2 inhalation. To determine whether
high-fat feeding and induction of insulin resistance (19)
modiﬁes the effects of Ex-4 on the exocrine pancreas,
4-week-old wild-type male mice were fed either standard
rodent diet or high-fat diet (45% kcal from fat) for 8 weeks;
during the last 4 weeks mice on high-fat diet were given
twice daily intraperitoneal injections of PBS or Ex-4 (24
nmol/kg). Separately, to assess the impact of diabetes on
the GLP-1R–dependent regulation of exocrine pancreatic
gene expression, 13-week-old male C57BL/6 mice were
maintained on a high-fat diet for 8 weeks, given one dose
of streptozotocin (STZ, 100 mg/kg), and after 4 more
weeks were allocated to four treatment groups for an
additional 8 weeks of 1) high-fat diet and twice daily
intraperitoneal injections of PBS, 2) high-fat diet and
metformin (500 mg  kg
1  day
1) provided in the drinking
water, 3) high-fat diet and twice daily intraperitoneal
injections of Ex-4 (3 nmol/kg), or 4) high-fat diet and
sitagliptin (370 mg  kg
1  day
1) provided in the diet.
Preparation of serum and tissue samples. Animals
were killed by CO2 inhalation 1, 24, 72, or 144 h after the
ﬁnal caerulein injection. Blood samples were collected by
cardiac puncture, placed on ice for 30 min, and centrifuged
at 4°C for 10 min at 14,000 rpm, and serum was stored at
80°C. The pancreas was removed, weighed, placed on
ice, and cut into sections for RNA, protein, histology, and
edema analyses. For RNA isolation, a section of pancreas
was homogenized in TRIzol reagent (Invitrogen Life Tech-
nologies, San Diego, CA), frozen on dry ice, and stored at
80°C until further analysis. Tissue samples for histology
were ﬁxed in 10% neutral-buffered formalin for 24 h and
embedded in parafﬁn. Remaining tissue samples were snap
frozen in liquid nitrogen and stored at 80°C until further
analysis.
Evaluation of the severity of pancreatitis. Quantiﬁca-
tion of serum amylase was performed using the Phad-
ebas amylase test (Magle Life Sciences, Cambridge, MA)
using 10 l serum (20). Pancreatic edema (21) was
quantiﬁed by measuring tissue water content after des-
iccation to a constant weight at room temperature for
72 h (dry weight). The results were calculated and
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FIG. 3. Effect of prior exposure to Ex-4 on the severity of caerulein-induced acute pancreatitis. Mice were treated twice daily with PBS or 10
nmol/kg Ex-4 for 1 week followed by 5 hourly injections with the indicated concentrations of caerulein. A: Schematic representation of
experimental design. B: Pancreas weight shown as a percentage of the ﬁnal body weight (left panel) or absolute pancreas weight (right panel),
and pancreatic water content (edema) (C) and serum amylase (D) were assessed in mice 6 h after the initial caerulein injection. Shown are
means  SE, (C and D) means  SE (left panel), and individual serum amylase levels (right panel). #P < 0.05, ##P < 0.01 PBS versus Ex-4
treatment, *P < 0.05 saline versus caerulein treatment, n  4 in each group. E: Expression proﬁles of pancreatitis-associated genes in the
pancreas of mice treated with PBS or 10 nmol/kg Ex-4 for 1 week before caerulein administration as indicated above. Levels of the indicated
transcripts are plotted relative to levels from pancreata of control (PBS 1 week  saline treatment) group as determined by real-time
quantitative PCR normalized to the 18S rRNA content or cyclophillin mRNA levels (for STAT3, SOCS3, ndrg1, and iﬁtm3). Results are expressed
as means  SE. #P < 0.05 PBS versus Ex-4 treatment, *P < 0.05, **P < 0.01, ***P < 0.001, saline versus caerulein treatment, n  4 mice in each
group.
GLP-1 AND EXPERIMENTAL MURINE PANCREATITIS
2152 DIABETES, VOL. 58, SEPTEMBER 2009PAP
PBS Ex-4
0
10
20
30
40
50 0 (saline)
3 µg/kg caerulein
6 µg/kg caerulein
*
#
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
MCP-1
PBS Ex-4
0
20
40
60
80
100
120
140
*** ***
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
IL-6
PBS Ex-4
0
50
100
150
200
250 **
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
TNFα
PBS Ex-4
0
5
10
15
20
25
**
**
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
egr-1
PBS Ex-4
0
250
500
750
1000
1250
*
***
***
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
ATF3
PBS Ex-4
0
100
200
300
400
**
***
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
mist1
PBS Ex-4
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
****** ******
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
c-fos
PBS Ex-4
0
25
50
75
**
**
200
300
400
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
c-myc
PBS Ex-4
0.0
1.0
2.0
3.0
4.0 *
*
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
Anti-inflammatory:
Pro-inflammatory:
E
Transcription factors:
STAT3
PBS Ex-4
0
1
2
3 *** *** ***
***
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
SOCS3
PBS Ex-4
0
5
10
15
20
*
***
***
***
#
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
ifitm3
PBS Ex-4
0.0
0.5
1.0
1.5
2.0
* * ***
#
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
ndrg1
PBS Ex-4
0.0
2.0
4.0
6.0
8.0
10.0
12.0 ***
***
r
e
l
a
t
i
v
e
 
m
R
N
A
l
e
v
e
l
s
junB
PBS Ex-4
0
10
20
30
40
*
***
***
***
r
e
a
l
t
i
v
e
 
m
R
N
A
 
v
a
l
u
e
s
Reg IIIα
PBS Ex-4
0
5
10
15
20
25 #
r
e
l
a
t
i
v
e
 
m
R
N
A
 
v
a
l
u
e
s
FIG. 3. Continued.
J.A. KOEHLER AND ASSOCIATES
DIABETES, VOL. 58, SEPTEMBER 2009 2153expressed as a percentage of wet weight (wet
weightdry weight/wet weight  100).
RNA isolation and quantitative real-time PCR. RNA
from pancreatic tissue was extracted using TRIzol reagent;
after ﬁrst-strand cDNA synthesis, real-time quantitative
PCR was carried out as described (22). Quantiﬁcation of
transcript levels was performed with the ABI PRISM SDS
2.1 software. Cyclophilin mRNA or 18S rRNA was used for
normalization as expression of both remained unaltered
regardless of treatment.
Histology. Parafﬁn-embedded tissues were sectioned (5
m) and stained with hematoxylin-eosin. Immunohisto-
chemistry was carried out using indirect immunoperoxi-
dase detection with NovaRED substrate (Vector
Laboratories, Burlington, ON, Canada) followed by hema-
toxylin counterstaining. Primary rabbit polyclonal anti-
bodies were used at dilutions recommended by the
manufacturer and included: rabbit anti–c-fos (Sigma-Al-
drich), rabbit anti–egr-1 (Santa Cruz Biotechnology, Santa
Cruz, CA), and rat anti-mouse neutrophils (MCA771GA;
AbD Serotec, Kidlington, Oxford, U.K.).
Ex vivo pancreas preparation and cAMP assay. Pan-
creatic fragments were prepared from C57Bl/J6 mice.
Brieﬂy, the pancreas was rapidly cut into small pieces,
cultured in DMEM  1% BSA  10% trasylol, washed three
times with DMEM  1% BSA  5% trasylol, resuspended in
DMEM  1% BSA  10% trasylol, and aliquoted such that
each tube contained 4% of the entire pancreas. Prepara-
tions were then stimulated with 100 nmol/l Ex-4 or 20
mol/l forskolin for 15 or 30 min at 37°C and frozen on dry
ice. Samples were thawed, sonicated with ice-cold ethanol
(65% ﬁnal concentration), and cellular debris removed by
centrifugation at 13,000 rpm. cAMP was measured from
dried aliquots of ethanol extracts using a cAMP radioim-
munoassay kit (Biomedical Technologies, Stoughton, MA).
Statistical analysis. Statistical signiﬁcance was assessed
by one-way or two-way ANOVA using Bonferroni’s multi-
ple comparison post hoc test and, where appropriate, by
unpaired Student’s t test using GraphPad Prism 4 (Graph-
Pad Software, San Diego, CA). A P value of 0.05 was
considered to be statistically signiﬁcant.
RESULTS
Ex-4 acutely increases egr-1 and c-fos expression in
the exocrine pancreas. Mice treated with GLP-1R ago-
nists exhibit a signiﬁcant increase in pancreas weight (23)
that cannot be attributed solely to increased -cell mass. To
determine whether GLP-1R activation induces a program of
gene expression in the exocrine pancreas associated with
development of pancreatic growth or inﬂammation, we ex-
amined whether Ex-4 enhanced the expression of immediate
early genes known to play important roles in regulating cell
proliferation. Ex-4 rapidly and robustly increased pancreatic
levels of egr-1 and c-fos (Fig. 1A), c-myc, and junB mRNA
transcripts (supplementary Fig. 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-0626/DC1). Moreover, the egr-1 protein was not
upregulated in islets but was localized exclusively to nuclei
of cells within the exocrine pancreas (Fig. 1B), whereas
nuclear c-fos expression was observed in both islets and
exocrine tissue (Fig. 1C). Hence, GLP-1R activation induces a
robust induction of gene and protein expression in the
exocrine pancreas.
Treatment with Ex-4 induces expression of PAP.
Egr-1 is an early response gene that encodes a transcrip-
tion factor that regulates cell proliferation, growth, and
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2154 DIABETES, VOL. 58, SEPTEMBER 2009apoptosis (24). Induction of egr-1 expression occurs
early in the course of caerulein-induced pancreatitis,
and inﬂammation-related gene expression is attenuated
in egr-1
/ mice with experimental pancreatitis (25).
Accordingly, we examined whether agents that activate
the GLP-1Rs upregulate expression of genes associated
with pancreatitis. Mice were treated with Ex-4 for 1 week
(supplementary Fig. 2), and the expression of pancreatitis-
associated genes was assessed by real-time quantitative
PCR. Ex-4 (1 or 10 nmol/kg twice daily for 1 week)
increased pancreas weight (Fig. 2A) but had no effect on
levels of mRNA transcripts encoding the proinﬂammatory
mediators (monocyte chemotactic protein [Mcp]-1, intracel-
lular adhesion molecule-1, signal transducer and activator of
transcription [STAT]-3, ndrg1, or iﬁtm3) or transcription
factors (egr-1, activating transcription factor (ATF)-3, mist1,
c-fos, c-myc, and junB) associated with acute pancreatitis
(Fig. 2B and supplementary Table 1). In contrast, Ex-4
markedly increased pancreatic expression of the anti-inﬂam-
matory gene PAP (Reg III) and Reg III (Fig. 2B). The
increase in pancreatic weight and induction of PAP and
RegIII gene expression was not speciﬁc to Ex-4 but was
also observed in mice treated with the human GLP-1R
agonist liraglutide (Fig. 2C and D). These actions required a
functional GLP-1R as liraglutide had no effect on pancreatic
weight or induction of gene expression in Glp1r
/ mice
(Fig. 2Cand D). Moreover, liraglutide reduced the expression
of the proinﬂammatory transcription factor, STAT3, in wild-
ATF3
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/ mice (Fig. 2D). The expression
levels of most pancreatitis-associated mRNA transcripts
were comparable in Glp1r
/ versus Glp1r
/ pancreas;
however, basal levels of suppressor of cytokine signaling
(SOCS)-3 and STAT3 mRNA transcripts were lower in
Glp1r
/ mice (Fig. 2D). Taken together, these ﬁndings
demonstrate that structurally distinct GLP-1R agonists pro-
duce changes in pancreatic mass and gene expression,
actions requiring a functional GLP-1 receptor.
Effect of Ex-4 pretreatment on susceptibility to
caerulein-induced pancreatitis. To assess whether an-
tecedent activation of the GLP-1R increases the severity of
pancreatitis, mice were treated twice daily with Ex-4 for 1
week before exposure to caerulein (Fig. 3). A low dose of
caerulein was employed for these studies (3 or 6 g/kg)
based on preliminary experiments designed to induce a
detectable yet submaximal inﬂammatory response in the
pancreas (supplementary Fig. 3). Ex-4 signiﬁcantly in-
creased pancreas weight (Fig. 3B) whereas caerulein
alone produced a small increase in pancreas weight (Fig.
3B) and a modest increase in tissue edema (Fig. 3C).
Caerulein consistently produced a low but detectable level
of inﬂammation, as evidenced by increased pancreatic
edema, elevated serum amylase, neutrophil inﬁltration,
and upregulated egr-1 and c-fos expression in the exocrine
pancreas (supplementary Figs. 3 and 4, and data not
shown). Intriguingly, serum amylase levels were lower in
mice pretreated with Ex-4 and then treated with 3 g/kg
caerulein (Fig. 3D). Ex-4 did not signiﬁcantly modulate
levels of most pancreatitis-associated mRNA transcripts
regulated by caerulein administration with the exception
of Reg III and SOCS3 that were further induced in
Ex-4–treated mice exposed to caerulein (Fig. 3E). Consis-
tent with previous ﬁndings (Fig. 2A), treatment with Ex-4
for 1 week signiﬁcantly increased the transcript levels of
the anti-inﬂammatory protein PAP (Fig. 3E), in the pres-
ence or absence of caerulein.
Loss of GLP-1R signaling does not modify the sever-
ity of caerulein-induced pancreatitis. To determine
whether endogenous GLP-1R signaling inﬂuences suscep-
tibility to caerulein-induced pancreatitis, we assessed the
effects of a submaximal dose of caerulein on gene expres-
sion and severity of pancreatitis in Glp1r
/ versus
Glp1
/ mice. Pancreas weight, edema, and serum amy-
lase were not signiﬁcantly different in caerulein-treated
Glp1r
/ versus Glp1r
/ mice (Fig. 4B–D). Furthermore,
GLP-1R genotype had no effect on the expression of
pancreatic genes known to be induced by caerulein,
including SOCS3, Mcp-1, egr-1, ATF-3, and c-fos (Fig. 4E).
Intriguingly, caerulein-induced levels of PAP, RegIII,c -
myc, and junB mRNA transcripts were signiﬁcantly greater
in Glp1r
/ mice (Fig. 4E).
Ex-4 does not affect recovery from or severity of
caerulein-induced pancreatitis. To determine whether
GLP-1R agonists exacerbate the severity or prolong the
recovery after initiation of acute pancreatitis, mice were
treated with caerulein followed by 10 nmol/kg of Ex-4
twice daily for up to 6 days (Fig. 5A). Mice were killed
for analysis at 1, 24, 72 h, and 6 days after the ﬁnal
injection of caerulein. Caerulein transiently but signiﬁ-
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DIABETES, VOL. 58, SEPTEMBER 2009 2157cantly increased serum amylase (Fig. 5B, day 0), pan-
creatic edema (Fig. 5C, day 0), and relative pancreas
weight (Fig. 5D, day 1). However, serum amylase and
pancreatic edema returned to basal levels after 24 h,
independent of Ex-4 treatment (Fig. 5B and C). Simi-
larly, levels of mRNA transcripts encoding the proin-
ﬂammatory proteins Mcp-1, interleukin (IL)-6, and ndrg1
were rapidly induced by caerulein but returned to basal
levels within 24 h independent of Ex-4 treatment (Fig.
5E). Levels of STAT3 and iﬁtm3 transcripts were ele-
vated in Ex-4–treated mice (Fig. 5E), and mRNA tran-
scripts for the anti-inﬂammatory proteins PAP and
SOCS3 remained elevated in Ex-4–treated mice. In
contrast, mRNA transcripts for c-fos, c-myc, and junB
were transiently increased in the pancreas of caerulein-
treated mice but were not affected by concomitant Ex-4
treatment (Fig. 5E), whereas levels of pancreatic mRNA
transcripts for mist1 and egr-1 were modestly but sig-
niﬁcantly higher in Ex-4–treated mice.
Ex-4 modulates pancreatic gene expression in mice
with metabolic stress. To determine whether GLP-1R
activation modiﬁed the expression of pancreatitis-associated
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2158 DIABETES, VOL. 58, SEPTEMBER 2009genes in the setting of a mild metabolic stress associated with
the development of insulin resistance (19), mice were placed
on a high-fat diet and treated twice daily with saline or Ex-4
(Fig. 6A). Consistent with previous observations, Ex-4 pre-
vented weight gain (Fig. 6C) and signiﬁcantly increased
pancreas weight (Fig. 6B) but did not affect levels of serum
amylase (Fig. 6D). Moreover, high-fat diet mice treated with
saline, but not Ex-4, exhibited a signiﬁcant increase in the
transcript levels of pancreatitis-associated genes including
Mcp-1, STAT3, egr-1, and ATF-3 as well as the exocrine-
speciﬁc transcription factor mist1 (Fig. 6E). In contrast, Ex-4
(but not saline) administration signiﬁcantly increased levels
of mRNA transcripts for PAP, c-fos, c-myc, and junB (Fig.
6E).
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Ex-4, antidiabetic agents associated with enhanced GLP-1
receptor activation through various mechanisms (3,4,26),
modulated pancreatitis-associated gene expression proﬁles
in high-fat–fed diabetic mice. Ex-4, and to a lesser extent the
DPP-4 inhibitor sitagliptin, but not metformin increased PAP
mRNA transcript levels in diabetic mice (Fig. 7). Neither
Ex-4, metformin, nor sitagliptin treatment modulated the
expression of other genes associated with pancreatitis in-
cluding SOCS3, egr-1, STAT3, c-myc, or junB (Fig. 7B).
Finally, as Ex-4 was reported to exhibit high-afﬁnity binding
to guinea pig pancreatic acinar membranes and stimulate
cyclic AMP formation through a distinct receptor that pref-
erentially recognized Ex-4 relative to GLP-1 (27), we assessed
cyclic AMP formation in slices from wild-type mouse pan-
creas. Forskolin but not Ex-4 rapidly stimulated cyclic AMP
accumulation in pancreatic slices ex vivo (Fig. 8).
DISCUSSION
There are currently limited data regarding putative effects of
GLPs on the function of the normal or inﬂamed exocrine
pancreas. Intriguingly, coadministration of glucagon and
careulein attenuated the increase in pancreatic weight and
amylase expression seen in rats treated with careulein alone
(28). Similarly, oxyntomodulin, a peptide structurally related
to both glucagon and GLP-1, was shown to be 10-fold more
potent than glucagon in the suppression of rat pancreatic
exocrine secretion in the basal state or after administration
of caerulein (29). Our results extend these ﬁndings by dem-
onstrating that although acute and chronic GLP-1R activation
modulates a gene expression program in the exocrine murine
pancreas, GLP-1 receptor activation does not predispose to
or exacerbate experimental pancreatitis in mice.
Several lines of evidence imply that exocrine cells express
a functional GLP-1 and/or exendin receptor. Guinea pig
pancreatic acini contain high-afﬁnity binding sites for Ex-4,
and Ex-4 binding was displaced from acinar cells by coincu-
bation with native GLP-1 (27). Furthermore, both Ex-4– and
GLP-1–stimulated cAMP formation but not amylase release
in dispersed guinea pig pancreatic acini (27,30), and these
stimulatory actions on cAMP were blocked by the GLP-1R
antagonist exendin (9–39) (30,31). Similarly, Ex-4 stimulated
cyclic AMP formation in rat pancreatic slices, and potenti-
ated calcium ionophore-, neurotransmitter-, or CCK-induced
amylase release in vitro (32). In contrast, we found that
forskolin, but not Ex-4, rapidly increased cAMP formation in
murine pancreatic fragments. Whether these ﬁndings reﬂect
species-speciﬁc differences in the expression or signaling of
functional pancreatic Ex-4/GLP-1 receptors requires further
investigation.
We used the CCK agonist caerulein for studies of
experimental pancreatitis as previous data demonstrated a
functional interaction of CCK and GLP-1 signaling path-
ways in the endocrine and exocrine pancreas (32,33). Al-
though the expression of most pancreatitis-associated genes
was not further modiﬁed by administration of GLP-1R ago-
nists, we consistently detected upregulation of PAP after
chronic administration of Ex-4 to mice, in the presence or
absence of caerulein administration. Similarly, liraglutide
junB
PBS PBS Met Ex-4 Sit
0.0
0.5
1.0
1.5
2.0
2.5
HF + STZ NC
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
egr-1
PBS PBS Met Ex-4 Sit
0.0
1.0
2.0
3.0
4.0
HF + STZ NC
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
c-myc
PBS PBS Met Ex-4 Sit
0.0
0.4
0.8
1.2
1.6
HF + STZ NC
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
PAP
PBS PBS Met Ex-4 Sit
0
2
4
6
8
10
12
14
HF + STZ NC
*
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s SOCS3
PBS PBS Met Ex-4 Sit
0.0
0.5
1.0
1.5
2.0
HF + STZ NC
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
STAT3
PBS PBS Met Ex-4 Sit
0.0
0.5
1.0
1.5
2.0
2.5
HF + STZ NC
r
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
Transcription factors
Anti-inflammatory
8 0 12
sac
week
HFD
STZ
age
(weeks)
13 21 25
20
33
- Metformin 
- Ex-4 
- Sitagliptin
A
B
FIG. 7. Ex-4 increases PAP gene expression in diabetic mice. Mice on a
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1  day
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to 16 mm for Ex-4– versus metformin- versus sitagliptin-treated mice.
A: Schematic representation of experimental design. B: Expression
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ner, and basal levels of pancreatic PAP mRNA transcripts
were modestly reduced in Glp1r
/ mice.
PAP has been shown to be mitogenic, antiapoptotic, and
anti-inﬂammatory and is strongly induced early in the
course of inﬂammatory diseases such as pancreatitis,
Crohn’s disease, and ulcerative colitis (14). Moreover,
inhibition of PAP gene expression in rats augments the
severity of acute pancreatitis (34), and PAP knockout mice
exhibit more extensive inﬂammation after induction of
caerulein-induced pancreatitis (13), suggesting a protec-
tive role for PAP in the inﬂammatory response to cellular
injury. Hence, the induction of PAP after GLP-1R activa-
tion may represent a compensatory mechanism that serves
to limit damage to the exocrine pancreas.
Our studies of GLP-1R activation on gene expression and
the development of and/or recovery from pancreatitis were
motivated, in part, by clinical reports of acute pancreatitis in
diabetic patients treated with GLP-1R agonists (8,10). Our
ﬁndings do not support the hypothesis that GLP-1R activa-
tion sensitizes the murine pancreas to the development of
pancreatic inﬂammation. Similarly, we did not detect any
difference in the extent of pancreatic inﬂammation in
Glp1r
/ mice. Taken together, the available data demon-
strate that GLP-1R activation leads to increases in mass and
changes in expression of pancreatitis-associated genes but
does not modify pancreatitis susceptibility or severity in the
murine pancreas. Whether GLP-1R activation modiﬁes gene
expression, enzyme secretion, or pancreatic inﬂammation in
the human pancreas requires further analysis.
ACKNOWLEDGMENTS
These studies were supported in part by a grant from the
Canadian Institutes of Health Research and Hoffman La-
Roche. D.J.D. is supported by the Canada Research Chairs
Program.
The Drucker Lab has received operating grant support
from Novo Nordisk in conjunction with the studies of
liraglutide. No other potential conﬂicts of interest relevant
to this article were reported.
We thank B. Yusta, A. Maida, and D. Holland for
experimental assistance and helpful discussions.
REFERENCES
1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153–165
2. Brubaker PL, Drucker DJ. Glucagon-like peptides regulate cell prolifera-
tion and apoptosis in the pancreas, gut and central nervous system.
Endocrinology 2004;145:2653–2659
3. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1.
Diabetes 2004;53:2181–2189
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet 2006;368:1696–1705
5. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and
exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-
producing cells. Diabetes 1999;48:2358–2366
6. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits
gastropancreatic function by inhibiting central parasympathetic outﬂow.
Am J Physiol 1998;275:G984–G992
7. Wan S, Coleman FH, Travagli RA. Glucagon-like peptide-1 excites pancre-
as-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest
Liver Physiol 2007;292:G1474–G1482
8. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med
2008;358:1970–1971; discussion 1971–1972
9. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H,
Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus
glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a random-
ised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet
2009;373:473–481
10. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug
safety surveillance system to assess the risk of acute pancreatitis with
exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res
Opin 2009;25:1019–1027
11. Gaisano HY, Gorelick FS. New insights into the mechanisms of pancreati-
tis. Gastroenterology, 2009 [Epub ahead of print]
12. De Leon DD, Farzad C, Crutchlow MF, Brestelli J, Tobias J, Kaestner KH,
Stoffers DA. Identiﬁcation of transcriptional targets during pancreatic
growth after partial pancreatectomy and exendin-4 treatment. Physiol
Genomics 2006;24:133–143
13. Gironella M, Folch-Puy E, LeGofﬁc A, Garcia S, Christa L, Smith A, Tebar L,
Hunt SP, Bayne R, Smith AJ, Dagorn JC, Closa D, Iovanna JL. Experimental
acute pancreatitis in PAP/HIP knock-out mice. Gut 2007;56:1091–1097
14. Graf R, Schiesser M, Reding T, Appenzeller P, Sun LK, Fortunato F, Perren A,
Bimmler D. Exocrine meets endocrine: pancreatic stone protein and regen-
erating protein–two sides of the same coin. J Surg Res 2006;133:113–120
15. Saluja AK, Lerch MM, Phillips PA, Dudeja V. Why does pancreatic
overstimulation cause pancreatitis? Annu Rev Physiol 2007;69:249–269
16. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker
DJ. Extrapancreatic incretin receptors modulate glucose homeostasis,
body weight, and energy expenditure. J Clin Invest 2007;117:143–152
17. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the
bedside. Gastroenterology 2007;132:1127–1151
18. Willemer S, Elsasser HP, Adler G. Hormone-induced pancreatitis. Eur Surg
Res 1992;1 (Suppl.):29–39
19. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying
mechanisms and treatment of impaired glucose tolerance and type 2
diabetes. Diabetes 2004;3 (Suppl.):S215–S219
20. Kowalik AS, Johnson CL, Chadi SA, Weston JY, Fazio EN, Pin CL. Mice
lacking the transcription factor Mist1 exhibit an altered stress response
and increased sensitivity to caerulein-induced pancreatitis. Am J Physiol
Gastrointest Liver Physiol 2007;292:G1123–G1132
21. Singh VP, Bhagat L, Navina S, Sharif R, Dawra RK, Saluja AK. Protease-
activated receptor-2 protects against pancreatitis by stimulating exocrine
secretion. Gut 2007;56:958–964
22. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for
glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide
are essential for the sustained metabolic actions of vildagliptin in mice.
Diabetes 2007;56:3006–3013
23. Baggio LL, Huang Q, Cao X, Drucker DJ. The long-acting albumin-exendin-4
GLP-1R agonist CJC-1134 engages central and peripheral mechanisms regu-
lating glucose homeostasis. Gastroenterology 2008;134:1137–1147
24. Thiel G, Cibelli G. Regulation of life and death by the zinc ﬁnger
transcription factor Egr-1. J Cell Physiol 2002;193:287–292
25. Ji B, Chen XQ, Misek DE, Kuick R, Hanash S, Ernst S, Najarian R, Logsdon
CD. Pancreatic gene expression during the initiation of acute pancreatitis:
identiﬁcation of EGR-1 as a key regulator. Physiol Genomics 2003;14:59–72
26. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Biochem Biophys Res Commun 2002;298:779–784
27. Singh G, Eng J, Raufman JP. Use of 125I-[Y39]exendin-4 to characterize
exendin receptors on dispersed pancreatic acini and gastric chief cells
from guinea pig. Regul Pept 1994;53:47–59
28. Kash FF, Wood JG, Solomon T. Glucagon inhibition of cerulein-induced
hypertrophy of the exocrine pancreas. Pancreas 1988;3:11–17
29. Biedzinski TM, Bataille D, Devaux MA, Sarles H. The effect of oxyntomodu-
lin (glucagon-37) and glucagon on exocrine pancreatic secretion in the
conscious rat. Peptides 1987;8:967–972
30. Raufman J-P, Singh L, Singh G, Eng J. Truncated glucagon-like peptide-1
interacts with exendin receptors on disperced acini from guinea pig
pancreas. Identiﬁcation of a mammalian homolgue of the reptilian peptide
exendin-4. J Biol Chem 1992;267:21432–21437
31. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and
characterization of exendin-4, an exendin-3 analogue, from Heloderma
suspectum venom. Further evidence for an exendin receptor on dispersed
acini from guinea pig pancreas. J Biol Chem 1992;267:7402–7405
32. Malhotra R, Singh L, Eng J, Raufman JP. Exendin-4, a new peptide from
Heloderma suspectum venom, potentiates cholecystokinin-induced amy-
lase release from rat pancreatic acini. Regul Pept 1992;41:149–156
33. Fehmann HC, Goke B, Weber V, Goke R, Trautmann ME, Richter G, Arnold
R. Interaction of glucagon-like peptide-1 (7–36)amide and cholecystoki-
nin-8 in the endocrine and exocrine rat pancreas. Pancreas 1990;5:361–365
34. Zhang H, Kandil E, Lin YY, Levi G, Zenilman ME. Targeted inhibition of
gene expression of pancreatitis-associated proteins exacerbates the sever-
ity of acute pancreatitis in rats. Scand J Gastroenterol 2004;39:870–881
J.A. KOEHLER AND ASSOCIATES
DIABETES, VOL. 58, SEPTEMBER 2009 2161